AllianceBernstein
VKTX icon

AllianceBernstein’s Viking Therapeutics VKTX Stock Holding History

AllianceBernstein’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
34,550
+7,881
+30% +$255K ﹤0.01% 2332
2026
Q1 		$938K Sell
26,669
-2,815
-10% -$90.5K ﹤0.01% 2368
2025
Q4 		$1.04M Buy
29,484
+2,616
+10% +$92.7K ﹤0.01% 2321
2025
Q3 		$706K Buy
26,868
+1,108
+4% +$33.1K ﹤0.01% 2507
2025
Q2 		$683K Sell
25,760
-1,013,657
-98% -$26.7M ﹤0.01% 2482
2025
Q1 		$25.1M Sell
1,039,417
-75,651
-7% -$2.39M 0.01% 808
2024
Q4 		$44.9M Buy
1,115,068
+81,183
+8% +$4.63M 0.02% 628
2024
Q3 		$65.5M Sell
1,033,885
-207,240
-17% -$12.2M 0.02% 535
2024
Q2 		$65.8M Sell
1,241,125
-319,753
-20% -$21M 0.02% 527
2024
Q1 		$128M Sell
1,560,878
-2,113,057
-58% -$94M 0.05% 334
2023
Q4 		$68.4M Buy
3,673,935
+123,861
+3% +$1.62M 0.03% 507
2023
Q3 		$39.3M Buy
3,550,074
+588,513
+20% +$8.42M 0.02% 628
2023
Q2 		$48M Buy
2,961,561
+2,947,905
+21,587% +$61.8M 0.02% 588
2023
Q1 		$227K Buy
+13,656
New +$141K ﹤0.01% 2869
2022
Q2 		– Sell
-79,600
Closed -$239K – 3386
2022
Q1 		$239K Buy
79,600
+200
+0.3% +$717 ﹤0.01% 2951
2021
Q4 		$365K Hold
79,400
– – ﹤0.01% 2872
2021
Q3 		$499K Hold
79,400
– – ﹤0.01% 2757
2021
Q2 		$476K Buy
79,400
+14,400
+22% +$85.5K ﹤0.01% 2833
2021
Q1 		$411K Sell
65,000
-12,200
-16% -$85.8K ﹤0.01% 2756
2020
Q4 		$435K Hold
77,200
– – ﹤0.01% 2655
2020
Q3 		$449K Sell
77,200
-2,500
-3% -$17.2K ﹤0.01% 2575
2020
Q2 		$575K Sell
79,700
-3,900
-5% -$25.9K ﹤0.01% 2515
2020
Q1 		$391K Buy
83,600
+13,300
+19% +$81.8K ﹤0.01% 2479
2019
Q4 		$564K Hold
70,300
– – ﹤0.01% 2501
2019
Q3 		$484K Hold
70,300
– – ﹤0.01% 2565
2019
Q2 		$583K Hold
70,300
– – ﹤0.01% 2538
2019
Q1 		$699K Buy
70,300
+4,000
+6% +$33.5K ﹤0.01% 2405
2018
Q4 		$507K Buy
66,300
+2,500
+4% +$29.9K ﹤0.01% 2474
2018
Q3 		$1.11M Hold
63,800
– – ﹤0.01% 2281
2018
Q2 		$605K Buy
+63,800
New +$424K ﹤0.01% 2545

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AllianceBernstein's VKTX Position: Q2 2026 in Review

AllianceBernstein increased its Viking Therapeutics (VKTX) stake by 30% in Q2 2026, buying an estimated $255K and bringing the position to 34,550 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

AllianceBernstein first reported a position in VKTX in Q2 2018 and has held it in 30 quarters since. The position peaked at $128M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • AllianceBernstein held 34,550 shares of Viking Therapeutics worth $1.12M as of Q2 2026.
  • AllianceBernstein bought 7,881 Viking Therapeutics shares in Q2 2026, an estimated $255K.
  • Viking Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2332 holding.
  • AllianceBernstein first reported a position in Viking Therapeutics in Q2 2018 and has held it in 30 quarters since.
  • AllianceBernstein's Viking Therapeutics position peaked at $128M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.